Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK 3012 in Actinic Keratosis
NCT01757613Phase 2Completed
- Sponsor
- Dolorgiet GmbH & Co. KG
- Start
- Dec 2012
- Primary completion
- Jan 2014
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AK-3012 in actinic keratosis (AK), sponsored by Dolorgiet GmbH & Co. KG. Started Dec 2012; status: completed.
02
Drugs
AK-3012
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT01757613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01757613.